FindTrial
Sign In

Antibody response after Covid-19 vaccine alongwith Kabasura Kudineer

A prospective, double blind, randomized clinical study to evaluate the antibody response after Covid-19 vaccine when provided along with Kabasura Kudineer, a siddha medicine

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033857
Enrollment
500
Registered
2021-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Kabasura Kudineer tablet: 2 tablets will be taken orally, twice a day- Morning and Night after food for 12 weeks Initiated on the day of the first dose of the vaccine

Sponsors

Sri Sri Institute of Advance Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria -Persons without a history of SARS-CoV-2 infection -Participants yet to receive Covid-19 vaccine. -Residence within a 10-kilometre radius of AIIMS hospital

Exclusion criteria

Exclusion criteria: -Patients with associated comorbidities like hypertension, type 2 or type 1 diabetes or chronic or acute renal failure or any major systemic illness -Patients on Immuno-suppression therapy -Pregnant Women or lactating mothers

Design outcomes

Primary

MeasureTime frame
Change from baseline in antibodies count following 4 weeks after first dose of vaccine, 4 weeks after second dose of vaccine and at 6-8 weeks after 2nd dose.Timepoint: Baseline, 4 weeks after first dose of vaccine, 4 weeks after second dose of vaccine and 6-8 weeks after 2nd dose of vaccine.—

Secondary

MeasureTime frame
NoneTimepoint: None—

Countries

India

Contacts

Public ContactANJU DHAWAN

AIIMS

DRANJUDHAWAN@GMAIL.COM9818329539

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026